- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04978142
MaST: MEG and Brain Stimulation in Tinnitus (MaST)
Transcranial Modulation of Oscillatory Brain Activity in People With Tinnitus: A Concurrent Transcranial Direct Current Stimulation (tDCS) - Magnetoencephalography (MEG) Study
Tinnitus is the awareness of a sound in the ear or head without any outside source. It affects around 15% of people in the UK. About 20% of people with tinnitus experience symptoms that negatively affect their quality of life including sleep disturbances, difficulties with hearing and concentration, social isolation, anxiety, depression, irritation or stress. Most common clinical management strategies for tinnitus include education and advice combined with some form of sound therapy. The effects of these management options are, however, variable. Currently, the exact aetiology of tinnitus is unknown although maladaptive plasticity due to sensorineural hearing loss is thought to play a big role. Neuroimaging studies have pointed to over-activation or excessive spontaneous activity within the central auditory cortex. Furthermore, electrophysiological techniques have confirmed the frontal cortex's role in tinnitus through dysfunctional top-down modulation.
Transcranial direct current stimulation (tDCS) is a neurostimulation technique in which weak currents (1-2 mA's) are delivered to the brain, thereby depolarising or hyperpolarising neurons within the desired region of cortex. tDCS is a non-invasive and easy to apply tool, delivered by applying two surface electrode to a patients head. It has previously been used as a treatment for depression, stroke rehabilitation, and cognitive enhancement.
Some studies have indicated potential benefit of tDCS in tinnitus patients, but this has not yet been investigated within the UK. Neuromodulation therapies should deliver a permanent reduction in tinnitus percept by driving the neuroplastic changes necessary to interrupt abnormal levels of oscillatory cortical activity and restore typical levels of activity. This change in activity should alter or interrupt the tinnitus percept (reduce or extinguish) and this should be concomitant with a change in the level of self-reported tinnitus handicap. The currently ongoing Cochrane review of neuromodulation (desynchronisation) for tinnitus in adults found mixed evidence for the electrical stimulation therapies for tinnitus, including tDCS. However, the review also found that the most recent tDCS trials that have used greater numbers of treatment sessions found significant reductions in tinnitus symptom severity, anxiety, and depression. Authors concluded that these findings warrant further trials of tDCS. Research studies using electroencephalography (EEG) or magnetoencephalography (MEG) suggested changes in oscillatory activity in different frequency bands that might be associated with tinnitus, however a consistent picture has not yet emerged. Reduction of this abnormal activity might signify a reduction in the level or perceived severity of TI and could potentially be used as a valuable indicator of the course of TI treatment.
In this project specific changes in brain activity that happen during a new treatment approach for tinnitus - transcranial Direct Current Stimulation (tDCS)- will be investigated. This will help to determine how the treatment might work, whether specific brain activity may be a meaningful biological indicator or objective measure of tinnitus, and provide a reliable measure of treatment-related change; this has not yet been achieved in tinnitus research but is crucial.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, Reino Unido, NG1 5DU
- University of Nottingham, NIHR Nottingham Biomedical Research Centre
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Aged 18 years or over
- Have subjective tinnitus
- Able to read and understand English
- Safe to undergo tDCS (according to tDCS Safety Questionnaire)
- Safe to undergo MRI scanning (according to MRI Safety Screening Questionnaire)
Exclusion Criteria:
- Aged under 18 years
- No tinnitus
- Not able to read and understand English
- Not safe to undergo tDCS (according to tDCS Safety Questionnaire)
- Not safe to undergo MRI scanning (according to MRI Safety Screening Questionnaire)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Active
Active tDCS stimulation at 2 mA for 20 minutes, with a 10 seconds of ramp-up and 10 seconds of ramp-down time as used in previous tinnitus studies.
The stimulation will be delivered via two rubber electrodes attached using a layer of conductive paste (35 cm2).
The anode will be placed over the right dlPFC and cathode over the left dlPFC).
|
Non-invasive neuromodulation employing a direct current, applied using a DC STIMULATOR PLUS manufactured by NeuroConn Technology by NeuroCare.
This is a micro-processor-controlled constant current source.
It meets the highest safety standards thanks to (hardware- and software-based) multistage monitoring of the current path.
By continuously monitoring electrode impedance it can detect insufficient contact with the skin and automatically terminate stimulation.
This is a reliable method of avoiding any injury to the patient.
|
|
Comparador Falso: Sham
Placebo stimulation is performed using the same current intensity, but only applied for 45 seconds in addition to the 10 second ramp-up and 10 second ramp-down periods.
The electrode configuration and placement will be identical to the active stimulation.
|
Non-invasive neuromodulation employing a direct current, applied using a DC STIMULATOR PLUS manufactured by NeuroConn Technology by NeuroCare.
This is a micro-processor-controlled constant current source.
It meets the highest safety standards thanks to (hardware- and software-based) multistage monitoring of the current path.
By continuously monitoring electrode impedance it can detect insufficient contact with the skin and automatically terminate stimulation.
This is a reliable method of avoiding any injury to the patient.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Oscillatory activity
Prazo: Continuously for 10 minutes before the onset of the intervention, continuously for 20 minutes before the intervention, continuously for 10 minutes after the intervention
|
Change in oscillatory resting state activity as measured with magnetoencephalography (MEG)
|
Continuously for 10 minutes before the onset of the intervention, continuously for 20 minutes before the intervention, continuously for 10 minutes after the intervention
|
|
Connectivity
Prazo: Continuously for 10 minutes before the onset of the intervention, continuously for 20 minutes before the intervention, continuously for 10 minutes after the intervention
|
Change in functional neural connectivity as measured with magnetoencephalography (MEG)
|
Continuously for 10 minutes before the onset of the intervention, continuously for 20 minutes before the intervention, continuously for 10 minutes after the intervention
|
|
Tinnitus loudness
Prazo: Within 5 minutes after intervention
|
Loudness of tinnitus percept as measured by visual analogue scale (0-10) with a higher score meaning louder tinnitus
|
Within 5 minutes after intervention
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Blinding
Prazo: Within 5 minutes after intervention
|
Effectiveness of blinding using a questionnaire
|
Within 5 minutes after intervention
|
|
Adverse effects
Prazo: Within 5 minutes after intervention
|
Type and severity of adverse effects measured with adverse affects questionnaire
|
Within 5 minutes after intervention
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Magdalena N Sereda, PhD, NIHR Nottingham BRC / University of Nottingham
- Diretor de estudo: Bas Labree, MSc, NIHR Nottingham BRC / University of Nottingham
Publicações e links úteis
Publicações Gerais
- Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. J Physiol. 2000 Sep 15;527 Pt 3(Pt 3):633-9. doi: 10.1111/j.1469-7793.2000.t01-1-00633.x.
- Adjamian P, Sereda M, Hall DA. The mechanisms of tinnitus: perspectives from human functional neuroimaging. Hear Res. 2009 Jul;253(1-2):15-31. doi: 10.1016/j.heares.2009.04.001. Epub 2009 Apr 11.
- Adjamian P, Sereda M, Zobay O, Hall DA, Palmer AR. Neuromagnetic indicators of tinnitus and tinnitus masking in patients with and without hearing loss. J Assoc Res Otolaryngol. 2012 Oct;13(5):715-31. doi: 10.1007/s10162-012-0340-5. Epub 2012 Jul 12.
- Genitsaridi E, Partyka M, Gallus S, Lopez-Escamez JA, Schecklmann M, Mielczarek M, Trpchevska N, Santacruz JL, Schoisswohl S, Riha C, Lourenco M, Biswas R, Liyanage N, Cederroth CR, Perez-Carpena P, Devos J, Fuller T, Edvall NK, Hellberg MP, D'Antonio A, Gerevini S, Sereda M, Rein A, Kypraios T, Hoare DJ, Londero A, Pryss R, Schlee W, Hall DA. Standardised profiling for tinnitus research: The European School for Interdisciplinary Tinnitus Research Screening Questionnaire (ESIT-SQ). Hear Res. 2019 Jun;377:353-359. doi: 10.1016/j.heares.2019.02.017. Epub 2019 Mar 2.
- Faber M, Vanneste S, Fregni F, De Ridder D. Top down prefrontal affective modulation of tinnitus with multiple sessions of tDCS of dorsolateral prefrontal cortex. Brain Stimul. 2012 Oct;5(4):492-8. doi: 10.1016/j.brs.2011.09.003. Epub 2011 Oct 5.
- Yadollahpour A, Mayo M, Saki N, Rashidi S, Bayat A. A chronic protocol of bilateral transcranial direct current stimulation over auditory cortex for tinnitus treatment: Dataset from a double-blinded randomized controlled trial. F1000Res. 2018 Jun 12;7:733. doi: 10.12688/f1000research.14971.1. eCollection 2018.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 505-2003
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .